Navigation Links
UCLA stem cell scientists first to track joint cartilage development in humans
Date:12/13/2013

Stem cell researchers from UCLA have published the first study to identify the origin cells and track the early development of human articular cartilage, providing what could be a new cell source and biological roadmap for therapies to repair cartilage defects and damage from osteoarthritis.

Such transformative therapies could reach clinical trials within three years, said the scientists from UCLA's Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research.

The study, led by Dr. Denis Evseenko, an assistant professor of orthopedic surgery and head of UCLA's Laboratory of Connective Tissue Regeneration, was published online Dec. 12 in the journal Stem Cell Reports and will appear in a forthcoming print edition.

Articular cartilage, a highly specialized tissue formed from cells called chondrocytes, protects the bones of joints from forces associated with load-bearing and impact and allows nearly frictionless motion between the articular surfaces the areas where bone connects with other bones in a joint.

Cartilage injury and a lack of cartilage regeneration often lead to osteoarthritis, which involves the degradation of joints, including cartilage and bone. Osteoarthritis currently affects more than 20 million people in the U.S., making joint-surface restoration a major priority in modern medicine.

While scientists have studied the ability of different cell types to generate articular cartilage, none of the current cell-based repair strategies including expanded articular chondrocytes or mesenchymal stromal cells from adult bone marrow, adipose tissue, sinovium or amniotic fluid have generated long-lasting articular cartilage tissue in the laboratory.

For the current study, Evseenko and his colleagues used complex molecular biology techniques to determine which cells grown from embryonic stem cells, which can become any cell type in the body, were the progenitors of cartilage cells, or chondrocytes. They then tested and confirmed the growth of these progenitor cells into cartilage cells and monitored their growth progress, observing and recording important genetic features, or landmarks, that indicated the growth stages of these cells as they developed into the cartilage cells.

By bridging developmental biology and tissue engineering, Evseenko's discoveries represent a critical "missing link," providing scientists with checkpoints to tell if the cartilage cells are developing correctly.

"We began with three questions about cartilage development," Evseenko said. "We wanted to know the key molecular mechanisms, the key cell populations and the developmental stages in humans. We carefully studied how the chondrocytes developed, watching not only their genes but other biological markers that will allow us to apply the system for the improvement of current stem cellbased therapeutic approaches."

The research was also the first to employ the highest animal-free standards in attempting to generate all the key landmarks that allow the development of cell types that could be used in treatments to regrow damaged human cartilage. Stem cells are often grown using animal-based components, which help the stem cells flourish and grow, but such components can lead to unwanted variations and contamination. Evseenko's research process did not rely on any animal components, thus allowing for the potential production of therapies, such as stem cell serums, that are safe for humans.

Evseenko noted that in a living organism, more than one cell type is responsible for the complete regeneration of tissue, so in addition to the studies involving the generation of articular cartilage from human stem cells, he and his team are trying different protocols using various combinations of adult progenitor cells present in the joint to regenerate cartilage until the best one is found for therapeutic use.

With the progenitor cells and the landmarks of proper cartilage development identified, Evseenko believes that an effective cellular therapy for diseased or damaged joint cartilage could be tested in human trials within three years. Such stem cellbased therapies could make many current knee and hip replacement surgeries unnecessary, offering patients the ability to regrow lost cartilage, keep their bones intact and avoid the discomfort and risk of major joint-replacement surgery.


'/>"/>

Contact: Shaun Mason
smason@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
Source:Eurekalert

Related biology news :

1. Sniffing out danger: Rutgers scientists say fearful memories can trigger heightened sense of smell
2. Scientists map food security and self-provision of major cities
3. Scientists identified T372R mutation as potential target for diagnosis and treatment of insulinoma
4. Gene-silencing data now publicly available to help scientists better understand disease
5. Eurofins scientists discover genetic differences between identical twins
6. Oregon scientists offer new insights on controlling nanoparticle stability
7. Argonne scientists Rajh, Soderholm and Segre named AAAS Fellows
8. Deep Carbon Observatory scientists discover quick recipe for producing hydrogen
9. Stanford scientists probe abandoned mine for clues about permanent CO2 sequestration
10. A*STAR scientists discover novel hormone essential for heart development
11. Scientists unearth secrets of Périgord truffles, the culinary black diamond
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:4/14/2016)... TEL AVIV, Israel , April 14, 2016 /PRNewswire/ ... in Behavioral Authentication and Malware Detection, today announced the ... has already assumed the new role. Goldwerger,s ... for BioCatch, on the heels of the deployment of ... In addition, BioCatch,s behavioral biometric technology, which discerns unique ...
Breaking Biology News(10 mins):
(Date:5/26/2016)... -- Despite the volatility that continues to envelop ... pre-market research on ActiveWallSt.com directs the investor community,s focus on ... RDUS ), Cerus Corp. (NASDAQ: CERS ), Arrowhead ... Therapeutics Inc. (NASDAQ: FPRX ). Register with us ... http://www.activewallst.com/ On Wednesday, shares in ...
(Date:5/25/2016)... ... 2016 , ... Lajollacooks4u has become a rising hotspot for specialized team building ... top attractions. Fortune 500 companies, such as Illumina, Hewlett-Packard, Qualcomm and Elsevier, have ... experience. , Each event kicks off with an olive oil and salt-tasting competition. ...
(Date:5/25/2016)... ... 25, 2016 , ... The American Medical Informatics Association (AMIA) ... National Coordinator for Health IT (ONC) outlining a measurement approach to interoperability that ... when and where it was needed. The organization of health informatics professionals said ...
(Date:5/25/2016)... Haven, Connecticut (PRWEB) , ... May 25, 2016 ... ... that the U.S. Food and Drug Administration (FDA) has granted the company’s orphan ... is the company’s second orphan drug designation granted by the FDA. , ...
Breaking Biology Technology: